Roan (Ulinastatin) in the Complex Therapy of Obstetric Sepsis: Effects on IL-6 and TNF-α Levels and Clinical Outcomes

Obstetric sepsis is a leading cause of maternal morbidity and mortality worldwide, largely due to systemic inflammatory response and cytokine storm. This study evaluated the effectiveness of Roan (ulinastatin), a protease inhibitor, as part of complex therapy for obstetric sepsis. A total of 40 patients with moderate obstetric sepsis were enrolled and divided into two groups: standard therapy plus Roan (100,000 IU intravenously twice daily for five days) and standard therapy alone. Key clinical parameters, laboratory indices, and cytokine levels (IL-6 and TNF-α) were assessed on days 1 and 7. By day 7, the Roan group showed significant reductions in IL-6 (58%) and TNF-α (52%) compared to the control group (24% and 19% reductions, respectively; p<0.05). Clinical stabilization occurred 2.3 days earlier, and hospitalization was shortened by 3.1 days in the Roan group. These findings demonstrate that Roan effectively suppresses excessive inflammation, improves clinical outcomes, and is well tolerated. The study supports incorporating Roan into intensive care protocols for obstetric sepsis, while highlighting the need for larger multicenter trials to validate dosage, duration, and long-term outcomes.